APO-MELOXICAM TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

MELOXICAM

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

M01AC06

INN (আন্তর্জাতিক নাম):

MELOXICAM

ডোজ:

15MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

MELOXICAM 15MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0131676004; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2004-02-03

পণ্য বৈশিষ্ট্য

_APO-MELOXICAM (Meloxicam Tablets) _
_ _
_Page 1 of 49 _
PRODUCT MONOGRAPH
PR
APO-MELOXICAM
MELOXICAM TABLETS
7.5 mg and 15 mg
APOTEX STANDARD
NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
APOTEX INC.
DATE OF PREPARATION:
150 Signet Drive
February 03, 2004
Toronto, Ontario
M9L 1T9
DATE OF REVISION:
September 25, 2023
SUBMISSION CONTROL NO: 274891
_APO-MELOXICAM (Meloxicam Tablets) _
_ _
_Page 2 of 49 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................
5
ADVERSE REACTIONS
............................................................................................................
16
DRUG INTERACTIONS
............................................................................................................
23
DOSAGE AND ADMINISTRATION
........................................................................................
29
OVERDOSAGE
..........................................................................................................................
31
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
31
STORAGE AND STABILITY
....................................................................................................
35
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 36
PART II: SCIENTIFIC INFORMATION
..............................................................................
37
PHARMACEUTICAL INFORMATION
.......................................................